[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562781":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":139,"collaborators":19,"id":141,"slug":142,"hasResults":143,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":19,"eligibilityCriteria":147,"healthyVolunteers":143,"sex":148,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":19,"studyType":154,"phases":155,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},{"fullName":5,"class":6},"Alexion Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gefurulimab","EXPERIMENTAL","On Day 1, participants will receive a weight based loading dose followed by a weekly maintenance dose for up to 122 weeks.",[13],"Combination Product: Gefurulimab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"COMBINATION_PRODUCT","Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Alexion Pharmaceuticals, Inc. (Sponsor)","CONTACT","1-855-752-2356","clinicaltrials@alexion.com",[27,41,50,60,68,76,84,89,94,105,113,121,131],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"Research Site","RECRUITING","Washington D.C.","District of Columbia","20010","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-77.03637,38.89511,{"lat":39,"lon":38},{"facility":28,"status":29,"city":42,"state":43,"zip":44,"country":33,"countryCode":34,"cosmosGeoPoint":45,"geoPoint":49,"contacts":19},"Norfolk","Virginia","23507",{"type":36,"coordinates":46},[47,48],-76.28522,36.84681,{"lat":48,"lon":47},{"facility":28,"status":29,"city":51,"state":19,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":59,"contacts":19},"Joinville","89202-451","Brazil","BR",{"type":36,"coordinates":56},[57,58],-48.84556,-26.30444,{"lat":58,"lon":57},{"facility":28,"status":29,"city":61,"state":19,"zip":62,"country":53,"countryCode":54,"cosmosGeoPoint":63,"geoPoint":67,"contacts":19},"Salvador","41253-190",{"type":36,"coordinates":64},[65,66],-38.49096,-12.97563,{"lat":66,"lon":65},{"facility":28,"status":29,"city":69,"state":19,"zip":70,"country":53,"countryCode":54,"cosmosGeoPoint":71,"geoPoint":75,"contacts":19},"São José do Rio Preto","15090-000",{"type":36,"coordinates":72},[73,74],-49.37944,-20.81972,{"lat":74,"lon":73},{"facility":28,"status":29,"city":77,"state":19,"zip":78,"country":53,"countryCode":54,"cosmosGeoPoint":79,"geoPoint":83,"contacts":19},"São Paulo","0438-002",{"type":36,"coordinates":80},[81,82],-46.63611,-23.5475,{"lat":82,"lon":81},{"facility":28,"status":29,"city":77,"state":19,"zip":85,"country":53,"countryCode":54,"cosmosGeoPoint":86,"geoPoint":88,"contacts":19},"05403-000",{"type":36,"coordinates":87},[81,82],{"lat":82,"lon":81},{"facility":28,"status":29,"city":90,"state":19,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"Saitama-Shi","330-8777","Japan","JP",{"facility":28,"status":95,"city":96,"state":19,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":19},"WITHDRAWN","Bydgoszcz","85-065","Poland","PL",{"type":36,"coordinates":101},[102,103],18.00762,53.1235,{"lat":103,"lon":102},{"facility":28,"status":95,"city":106,"state":19,"zip":107,"country":98,"countryCode":99,"cosmosGeoPoint":108,"geoPoint":112,"contacts":19},"Lodz","93-338",{"type":36,"coordinates":109},[110,111],19.47395,51.77058,{"lat":111,"lon":110},{"facility":28,"status":29,"city":114,"state":19,"zip":115,"country":98,"countryCode":99,"cosmosGeoPoint":116,"geoPoint":120,"contacts":19},"Warsaw","02-097",{"type":36,"coordinates":117},[118,119],21.01178,52.22977,{"lat":119,"lon":118},{"facility":28,"status":29,"city":122,"state":19,"zip":123,"country":124,"countryCode":125,"cosmosGeoPoint":126,"geoPoint":130,"contacts":19},"New Taipei City","23561","Taiwan","TW",{"type":36,"coordinates":127},[128,129],121.45703,25.06199,{"lat":129,"lon":128},{"facility":28,"status":29,"city":132,"state":19,"zip":133,"country":124,"countryCode":125,"cosmosGeoPoint":134,"geoPoint":138,"contacts":19},"Taipei","11101",{"type":36,"coordinates":135},[136,137],121.52639,25.05306,{"lat":137,"lon":136},{"type":140,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100562781","phase-3-pk-pd-safety-and-efficacy-study-of-gefurulimab-in-pediatric-patients-with-achr-generalized-myasthenia-gravis-100562781",false,"NCT06607627","PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to \u003C 18 Years of Age) With Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)","Inclusion Criteria:\n\nUnited States of America (USA) specific inclusion criterion:\n\n* Participant must be 12 to \\\u003C 18 years of age at the time of signing the informed consent\u002Fassent.\n* All participants must be vaccinated against meningococcal infection from serogroups A, B, C, W, and Y within 3 years and at least 2 weeks prior to the first dose of study intervention administration.\n\nRest of World (ROW) specific inclusion criteria:\n\n* Participant must be 6 to \\\u003C 18 years of age at the time of signing the informed consent\u002Fassent.\n* All participants must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) within 3 years prior to study intervention on Day 1. If vaccination occurs \\\u003C 2 weeks prior to Day 1, the participants will receive prophylactic antibiotics for at least 2 weeks after initial meningococcal vaccination for serogroups A,C,W,Y (and B, where available)\n\nGlobal inclusion criteria:\n\n* Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV\n* Positive serological test for autoantibodies against AChR\n\nExclusion Criteria:\n\n* History of thymectomy, or any other thymic surgery within 12 months prior to Screening\n* Untreated thymic malignancy, carcinoma, or thymoma\n* History of Neisseria meningitidis infection\n* Pregnancy, breastfeeding, or intention to conceive during the course of the study","ALL","6 Years","17 Years",{"count":152,"type":153},12,"ESTIMATED","INTERVENTIONAL",[156],"PHASE3","The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.",[159,160],"Generalized Myasthenia Gravis","gMG",[162,163,159,160,164,165,166,167,168,169,170,171,172,173],"Acetylcholine Receptor antibodies","AChR+","ALXN1720","anti-acetylcholine receptor antibody-positive","acetylcholine receptor","AChR","myasthenia gravis","MG","complement component 5","C5","VHH antibody","pediatric","2026-03-31",{"date":176,"type":177},"2026-04-01","ACTUAL",{"date":179,"type":177},"2024-11-13",{"date":181,"type":153},"2029-01-23",{"name":5,"class":6},13]